Page last updated: 2024-08-16

sumatriptan and buspirone

sumatriptan has been researched along with buspirone in 21 studies

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (28.57)18.2507
2000's7 (33.33)29.6817
2010's8 (38.10)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Buckingham, J; Glen, RC; Hill, AP; Hyde, RM; Martin, GR; Robertson, AD; Salmon, JA; Woollard, PM1
Arrang, JM; Diaz, J; Leurs, R; Ruat, M; Schwartz, JC; Tardivel-Lacombe, J; Traiffort, E1
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Ahman, M; Holmén, AG; Wan, H1
Cleves, AE; Jain, AN; Kirshner, D; Langham, JJ; Spitzer, R1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Glen, RC; Lowe, R; Mitchell, JB1
Ekins, S; Williams, AJ; Xu, JJ1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Sussman, N1
Alessandri, M; Fanciullacci, M; Geppetti, P; Sicuteri, R1
Caffarri, G; Capretti, L; Chiodera, P; Coiro, V; Magotti, MG; Volpi, R1
Jain, NK; Kulkarni, SK1
Crema, F; De Ponti, F1
Camilleri, M; Coulie, BJ; Farrugia, G; Locke, GR; Meulemans, A; Schuurkes, JA; Szurszewski, JH; Xue, L1
Cataldo, S; Chiodera, P; Coiro, V; Maffei, ML; Minelli, R; Vacca, P; Volpi, R; Volta, E1

Reviews

2 review(s) available for sumatriptan and buspirone

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
The potential benefits of serotonin receptor-specific agents.
    The Journal of clinical psychiatry, 1994, Volume: 55 Suppl

    Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Humans; Isoxazoles; Ondansetron; Piperazines; Piperidines; Receptors, Serotonin; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin; Sumatriptan; Triazoles

1994

Trials

1 trial(s) available for sumatriptan and buspirone

ArticleYear
Buspirone, but not sumatriptan, induces miosis in humans: relevance for a serotoninergic pupil control.
    Clinical pharmacology and therapeutics, 1995, Volume: 57, Issue:3

    Topics: Administration, Oral; Adult; Analysis of Variance; Buspirone; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Miosis; Pupil; Receptors, Serotonin; Reference Values; Sumatriptan

1995

Other Studies

18 other study(ies) available for sumatriptan and buspirone

ArticleYear
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
    Journal of medicinal chemistry, 1995, Sep-01, Volume: 38, Issue:18

    Topics: Animals; Aorta; Computer-Aided Design; Drug Design; Haplorhini; In Vitro Techniques; Migraine Disorders; Models, Chemical; Rabbits; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1D; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Saphenous Vein; Serotonin Receptor Agonists; Structure-Activity Relationship; Tryptamines

1995
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.
    Proceedings of the National Academy of Sciences of the United States of America, 1993, Sep-15, Volume: 90, Issue:18

    Topics: Amino Acid Sequence; Animals; Base Sequence; Blotting, Northern; Brain; CHO Cells; Cricetinae; Cyclic AMP; DNA; Genomic Library; Kinetics; Lysergic Acid Diethylamide; Mianserin; Molecular Sequence Data; Multigene Family; Oligodeoxyribonucleotides; Organ Specificity; Rats; Receptors, Serotonin; Restriction Mapping; Serotonin; Serotonin Receptor Agonists; Transfection

1993
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations

2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
    Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6

    Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry

2009
Physical binding pocket induction for affinity prediction.
    Journal of medicinal chemistry, 2009, Oct-08, Volume: 52, Issue:19

    Topics: Binding Sites; Ligands; Models, Molecular; Neural Networks, Computer; Peptide Fragments; Protein Binding; Receptor, Serotonin, 5-HT1A

2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
Predicting phospholipidosis using machine learning.
    Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5

    Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
    Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3

    Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
Different effects of the serotonergic agonists buspirone and sumatriptan on the posterior pituitary hormonal responses to hypoglycemia in humans.
    Neuropeptides, 1996, Volume: 30, Issue:2

    Topics: Adult; Arginine Vasopressin; Buspirone; Humans; Hypoglycemia; Insulin; Male; Oxytocin; Pituitary Hormones, Posterior; Receptors, Serotonin; Serotonin Receptor Agonists; Sumatriptan

1996
L-NAME, a nitric oxide synthase inhibitor, modulates cholinergic antinociception.
    Methods and findings in experimental and clinical pharmacology, 1999, Volume: 21, Issue:3

    Topics: Acetic Acid; Analgesics; Animals; Buspirone; Cholinergic Agents; Drug Synergism; Enzyme Inhibitors; Female; Male; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pain; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Sumatriptan

1999
Treatment functional GI disease: the complex pharmacology of serotonergic drugs.
    British journal of clinical pharmacology, 2002, Volume: 54, Issue:6

    Topics: Buspirone; Cisapride; Gastrointestinal Diseases; Humans; Serotonin Agents; Serotonin Receptor Agonists; Sumatriptan

2002
Effect of modulation of serotonergic, cholinergic, and nitrergic pathways on murine fundic size and compliance measured by ultrasonomicrometry.
    American journal of physiology. Gastrointestinal and liver physiology, 2006, Volume: 290, Issue:1

    Topics: Animals; Atropine; Bethanechol; Buspirone; Gastric Fundus; Male; Mice; Muscle Contraction; Muscle, Smooth; Nitroglycerin; Reproducibility of Results; Serous Membrane; Signal Transduction; Sumatriptan; Ultrasonography

2006
Effect of serotonergic system on AVP secretion induced by physical exercise.
    Neuropeptides, 2010, Volume: 44, Issue:1

    Topics: Adult; Arginine Vasopressin; Blood Glucose; Buspirone; Exercise; Hemodynamics; Humans; Male; Ondansetron; Osmolar Concentration; Serotonin; Serotonin Receptor Agonists; Sumatriptan; Young Adult

2010